Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Placentabiologi vid hälsa och sjukdom

6 november 2026 uppdaterad av: University of Oxford

Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.

A major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.

This single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, voice, placenta, umbilical cord, umbilical cord blood, amniotic fluid and/or uterine vein blood samples.

Through examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.

Studieöversikt

Detaljerad beskrivning

The study is a non-interventional, observational study focused on sample collection and laboratory-based analyses to investigate the role of placental EVs and soluble factors in maternal and fetal health. The study will focus on understanding the molecular mechanisms underlying pre-eclampsia, gestational diabetes mellitus and fetal growth restriction, with the ultimate aim of identifying biomarkers and therapeutic targets. To achieve this, the study will recruit participants with healthy, pathological and predisposed pregnancies alongside non-pregnant healthy controls.

Studietyp

Observationell

Inskrivning (Beräknad)

1000

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

This study will recruit a diverse cohort of pregnant and non-pregnant participants to enable analysis of placental EVs and soluble factors across different physiological and pathological conditions.

Participants will include:

  • Pregnant women with pre-eclampsia, gestational diabetes mellitus or fetal growth restriction to allow the study of disease-specific alterations in EVs and systemic responses.
  • Pregnant women predisposed to pre-eclampsia to provide insights into risk factors and early-stage changes, aiding in biomarker discovery for prediction and prevention.
  • Pregnant women with healthy pregnancies to understand normal EV release and immune regulation.
  • Non-pregnant women to provide critical baseline data to differentiate the effects of pregnancy from underlying physiological processes.

Pregnant participants may be recruited at any gestational stage to ensure a comprehensive coverage of pregnancy progression.

Beskrivning

Inclusion Criteria:

  • Female, aged 18 years or above

  • Willing and able to give informed consent for participation in the study

  • Able to read and understand written and spoken English to comprehend study materials and give informed consent

  • Non-pregnant women in good general health OR pregnant women who fall into one of the following:

    • Healthy pregnancy
    • Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria
    • Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy
    • Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities
    • Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies

Exclusion Criteria:

  • Non-pregnant participants with active health conditions that could confound study outcomes
  • Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: OTHER
  • Tidsperspektiv: OTHER

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Gravida kvinnor diagnosticerade med preeklampsi

There are no interventions for this study

Gravida kvinnor med diagnostiserad graviditetsdiabetes

There are no interventions for this study

Gravida kvinnor diagnosticerade med tillväxthämning hos fostret

There are no interventions for this study

Friska gravida kvinnor

There are no interventions for this study

Friska icke-gravida kvinnor

There are no interventions for this study

Gravida kvinnor predisponerade för preeklampsi

There are no interventions for this study

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Enhanced understanding of the molecular and cellular mechanisms linking placental EVs to maternal systemic inflammation in PET and GDM.
Tidsram: Baseline and at delivery

Quantitative (number of particles/ml) and qualitative differences (protein cargo) in EV profiles

Baseline and at delivery

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Quantitative and qualitative differences in inflammatory immune cells
Tidsram: baseline and delivery

Quantitative (cells/ml) and qualitative (protein and RNA composition/mg cell) will be measured

baseline and delivery
Sensitivity, specificity and predictive value of EVs for identifying PET, GDM and other pregnancy complications
Tidsram: Baseline and delivery

Standard statistical analysis of EV parameters against clinical endpoints to derive sensitivity, specificity and PPV/NPV in these disease conditions

Baseline and delivery

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

16 december 2025

Primärt slutförande (Beräknad)

31 maj 2030

Avslutad studie (Beräknad)

31 maj 2030

Studieregistreringsdatum

Först inskickad

10 december 2025

Först inskickad som uppfyllde QC-kriterierna

9 mars 2026

Första postat (Faktisk)

13 mars 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2026

Senast verifierad

1 december 2025

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera